Revised Sapporo/Sydney classification criteria for APS
| APS is present if at least 1 clinical criterion and 1 laboratory criterion are met . |
|---|
| Clinical criteria |
| 1. Vascular thrombosis |
| One or more objectively confirmed arterial, venous or small vessel thrombosis in any tissue or organ. For histopathologic confirmation, thrombosis should be present without significant vessel wall inflammation. |
| 2. Pregnancy morbidity |
| a. One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation or |
| b. ≥1 premature birth of a morphologically normal neonate before the 34th week of gestation because of (1) eclampsia or severe pre-eclampsia defined according to standard definitions or (2) recognized features of placental insufficiency or |
| c. ≥3 unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded |
| Laboratory criteria |
| 1. Lupus anticoagulant present in plasma on ≥2 occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Haemostasis |
| 2. Anticardiolipin antibody of IgG and/or IgM isotype in serum or plasma, present in medium or high titer (>40 GPL or MPL, or >99th percentile) on ≥2 occasions, at least 12 weeks apart, measured by standardized ELISA |
| 3. Anti-β2 glycoprotein 1 antibody of IgG and/or IgM isotype in serum or plasma (in titer >99th percentile) present on ≥2 occasions, at least 12 weeks apart, measured by standardized ELISA |
| APS is present if at least 1 clinical criterion and 1 laboratory criterion are met . |
|---|
| Clinical criteria |
| 1. Vascular thrombosis |
| One or more objectively confirmed arterial, venous or small vessel thrombosis in any tissue or organ. For histopathologic confirmation, thrombosis should be present without significant vessel wall inflammation. |
| 2. Pregnancy morbidity |
| a. One or more unexplained deaths of a morphologically normal fetus at or beyond the 10th week of gestation or |
| b. ≥1 premature birth of a morphologically normal neonate before the 34th week of gestation because of (1) eclampsia or severe pre-eclampsia defined according to standard definitions or (2) recognized features of placental insufficiency or |
| c. ≥3 unexplained consecutive spontaneous abortions before the 10th week of gestation, with maternal anatomic or hormonal abnormalities and paternal and maternal chromosomal causes excluded |
| Laboratory criteria |
| 1. Lupus anticoagulant present in plasma on ≥2 occasions at least 12 weeks apart, detected according to the guidelines of the International Society on Thrombosis and Haemostasis |
| 2. Anticardiolipin antibody of IgG and/or IgM isotype in serum or plasma, present in medium or high titer (>40 GPL or MPL, or >99th percentile) on ≥2 occasions, at least 12 weeks apart, measured by standardized ELISA |
| 3. Anti-β2 glycoprotein 1 antibody of IgG and/or IgM isotype in serum or plasma (in titer >99th percentile) present on ≥2 occasions, at least 12 weeks apart, measured by standardized ELISA |
Adapted from Miyakis et al11 with permission.
ELISA, enzyme-linked immunosorbent assay.